Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original article

Post-acute COVID-19 condition in Saudi Arabia: A national representative study

Faten A. AlRadini¹,¹, Fahad Alamri², Muna S. Aljahany³,*¹, Yasir Almuzaini⁴,⁵, Yousef Alsofayan⁶,⁵, Anas Khan⁶,⁷, Nada Albogami⁸, Maha Abdulrahim⁹, Alanoud Almogbil¹⁰, Ahmed Alahmari¹¹

¹ Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
² Global Center of Mass Gatherings Medicine, Ministry of Health, Riyadh, Saudi Arabia
³ Global Center of Mass Gatherings Medicine, Ministry of Health, Riyadh, Saudi Arabia
⁴ General Directorate of Data and Research, Saudi Red Crescent Authority, Riyadh, Saudi Arabia
⁵ Global Center of Mass Gatherings Medicine, Ministry of Health, Riyadh, Saudi Arabia
⁶ Department of Emergency Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
⁷ Department of Psychiatry Medicine, National Security Hospital, Riyadh, Saudi Arabia
⁸ Research and Academic Accreditation Office, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
⁹ Research Unit, Researcher-Freelancer, Riyadh, Saudi Arabia

Article info

Article history:
Received 2 February 2022
Received in revised form 9 March 2022
Accepted 20 March 2022

Keywords:
SARS-CoV-2
Late symptoms
Persistent symptoms
Post-acute COVID-19 condition

Abstract

Background: Many survivors of COVID-19 have developed symptoms and diseases similar to those observed after severe acute respiratory syndrome (SARS). Therefore, this study aimed to characterize the symptoms that appear after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been eradicated and to determine their relationship with COVID-19 severity.

Methods: This multicenter, retrospective cross-sectional study was conducted in all eligible confirmed cases of SARS-CoV-2 infection from Saudi Arabia. Study participants were randomly selected using computerized random sampling from a population of 314,821 patients. Descriptive statistics were used to describe baseline demographic data and clinical characteristics. Categorical variables were presented as counts and percentages, while continuous variables were presented as means and standard deviations.

Results: Approximately 70% of patients were found to have five or fewer symptoms simultaneously. Late symptoms (in the ongoing symptomatic COVID-19) occurred in 225 (22·5%) patients with the most common late symptoms being loss of smell, loss of taste, fatigue, shortness of breath, and cough (52·4%, 31·1%, 11·5%, 10·2%, and 8·9% of patients with late symptoms, respectively). We also found that the presence of acute symptoms of COVID-19 and admission to the hospital were significant independent predictors of the post-COVID-19 condition.

Conclusion: Saudi patients with COVID-19 develop a wide range of symptoms, similar to those observed and reported in other countries. The loss of smell, the loss of taste, shortness of breath, and fatigue were the...
main persistent symptoms. Regular follow-up of COVID-19 survivors is highly recommended to minimize the burden of the post-acute COVID-19 condition and improve the quality of life of patients.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.

**Introduction**

The novel coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been declared as a global pandemic by the World Health Organization (WHO) [1-3]. At the beginning of 2022, approximately 304,513,000 individuals were infected with SARS-CoV-2, and 5,483,562 lives have been lost worldwide [1]. The disease affects the physical and mental health of individuals who become infected. Economic and social difficulties markedly increase every day due to the distress and fear faced by combating this rampant virus [4].

Saudi Arabia is one of the countries that battled the pandemic in its early phases [5]. The first case of COVID-19 was discovered in March 2020, and once the first wave of COVID-19 had ended, 557,082 individuals had been infected with SARS-CoV-2 and 8,878 deaths were reported at the end of 2021 [1]. The second COVID-19 wave is currently in its early stages in Saudi Arabia, while the fourth wave has already started in some countries. This rapid progression has been driven by emerging variants of the virus, which have required new preventive measures to combat the emergence of each variant [6]. According to the WHO, COVID-19 has many variants; the variants of concern (VOCs) are Alpha, Beta, Gamma, Delta, and Omicron, and the variants of interest (VOIs) are Lamda and Mu [7]. VOCs may be associated with any of the following: increased transmissibility; increased virulence; detrimental changes in the epidemiology or presentation of COVID-19; and decreased effectiveness of preventive measures, diagnostics, vaccines, or therapeutics. VOIs are also associated with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, and immune, diagnostic or therapeutic escape [7,8].

Patients present with symptoms such as fever, dry cough, and fatigue, which are moderate in around 80% of cases, but severe cases of the disease might proceed to respiratory distress, respiratory failure, or multi-organ failure (MOF), necessitating admission to an intensive care unit (ICU) [9,10]. The long-term effects of acquiring SARS-CoV-2 remain unclear given the novelty of the outbreak. Most individuals infected with COVID-19 recover completely; however, a small percentage of patients infected with SARS-CoV-2 experience recurring difficulties years later, and exhibit symptoms associated with the so-called “post-COVID-19 syndrome” or “post-COVID-19 condition” [11].

The post-acute COVID-19 condition is characterized by a wide range of new, returning, or chronic health problems that present 4 weeks or more after being infected with SARS-CoV-2 [12]. The post-acute COVID-19 condition consists of subacute/ongoing COVID-19 and chronic or post-COVID-19 syndrome. Subacute/ongoing COVID-19 includes symptoms that appear 4–12 weeks after the onset of acute COVID-19, while chronic or post-COVID-19 syndrome includes symptoms that persist or appear beyond 12 weeks after the onset of acute COVID-19 and are not attributable to other diagnoses [13,14]. Individuals often report experiencing different combinations of the following symptoms: rash, fever, diarrhea, sleep disorders, dizziness, cough, chest or stomach pain, tiredness or fatigue, difficulty breathing, difficulty thinking or concentrating, mood changes, changes in menstrual period cycles, and changes in smell or taste [15]. Furthermore, post-acute COVID-19 conditions can be associated with MOF, including cardiovascular, pulmonary, renal, and neuropsychiatric organ systems [16]. Although extremely rare, some patients, especially children, develop multisystem inflammatory syndrome (MIS) during or shortly after contracting COVID-19 [17]. Various areas of the body can become inflamed due to MIS, which may eventually lead to MOF. Therefore, this study aimed to investigate and characterize the post-acute COVID-19 condition and its relationship with the severity of the disease.

**Methods**

**Study design**

This national cross-sectional study was conducted over a six-month period from March 2020 to August 2020, as authors collaborated from the Saudi Ministry of Health and Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. The study participants were randomly selected from a population of 314,821 patients registered at the Ministry of Health Database. All participants were informed about their enrollment in the study and oral consents were obtained through phone interviews. During the collection, handling, and storage of data, the ethical standards of the Declaration of Helsinki were followed, and all precautions were taken to ensure participant confidentiality. The study protocol was approved by the Institutional Review Board (IRB) of Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia (No: 21–0172).

**Inclusion and exclusion criteria**

The study included all patients diagnosed with COVID-19 who were at least 18 years old. We excluded patients who died during acute illness and patients who refused to consent for participation and provide all requested information.

**Sample size calculation**

Raosoft* software was used to determine the sample size calculation; to obtain a 95% confidence interval, a response distribution of 50%, and a 5% margin of error, the target sample size was estimated to be 371 participants. Adjusting the calculation for the projected 10% attrition, the final sample size was estimated to be 415 participants.

**Data collection**

Two public health specialists and two family physicians evaluated the questionnaire before and after it was translated into Arabic. Eight health practitioners (trained by the experts in the field), interviewed all participants and recorded all information using a designated data collection form. Oral consents and interviews were obtained by phone through the “937” Ministry of Health call center.
An independent reviewer resolved any discrepancies between the collected data and medical records. The questionnaire included sociodemographic data such as age; sex and occupation; questions about the medical history related to COVID-19, including a history of medical illness, hospital or ICU admission; history of smoking; questions about the ongoing symptomatic COVID-19; and questions about the post-COVID-19 condition. Acute SARS-CoV-2 infection was defined as signs and symptoms of COVID-19 lasting for up to 4 weeks. Ongoing symptomatic COVID-19 was defined as signs and symptoms of COVID-19 from 4 weeks to 12 weeks. Post-COVID-19 condition was defined as signs and symptoms that developed during or after an infection consistent with COVID-19, continuing for more than 12 weeks, and not explained by an alternative diagnosis. 15.

Table 1
The demographic data of the entire study population (n = 1000 patients).

| Characteristic | n   | %   |
|----------------|-----|-----|
| Age (range 21–81), years | 36.9 ± 11.9 |
| < 30            | 368 | 36.8|
| 31–40          | 311 | 31.1|
| 41–50          | 180 | 18.0|
| 51–60          | 99  | 9.9 |
| > 60           | 42  | 4.2 |
| Sex            |     |     |
| Female         | 395 | 39.5|
| Male           | 605 | 60.5|
| Occupation     |     |     |
| Employed       | 565 | 56.5|
| Not working    | 292 | 29.2|
| Retired        | 67  | 6.7 |
| Healthcare employed | 52  | 5.2 |
| Student        | 24  | 2.4 |
| Smoking        |     |     |
| Never          | 719 | 71.9|
| Current        | 201 | 20.1|
| Past           | 79  | 7.9 |

An independent reviewer resolved any discrepancies between the collected data and medical records. The questionnaire included sociodemographic data such as age; sex and occupation; questions about the medical history related to COVID-19, including a history of medical illness, hospital or ICU admission; history of smoking; questions about the ongoing symptomatic COVID-19; and questions about the post-COVID-19 condition. Acute SARS-CoV-2 infection was defined as signs and symptoms of COVID-19 lasting for up to 4 weeks. Ongoing symptomatic COVID-19 was defined as signs and symptoms of COVID-19 from 4 weeks to 12 weeks. Post-COVID-19 condition was defined as signs and symptoms that developed during or after an infection consistent with COVID-19, continuing for more than 12 weeks, and not explained by an alternative diagnosis. 15.

Statistical analysis

Descriptive statistics were used to describe the baseline demographic data and clinical characteristics. Categorical variables were presented as counts and percentages, whereas continuous variables were presented as means and standard deviations (SDs). The t-test was used for continuous variables, and the chi-squared test was used for categorical variables. Simple and multiple logistic regression analyses were performed to identify factors associated with the appearance of COVID-19 symptoms 4 weeks after the diagnosis; odds ratios (OR), adjusted odds ratios (aORs) and 95% confidence intervals (CI) were calculated. A p-value of less than 0.05 was considered significant. Statistical analyses were performed using the Statistical Package of Social Science (SPSS vers. 24; IBM Corp., Armonk, NY, USA).

Results

Baseline characteristics of the study population

A total of 1000 participants with confirmed SARS-CoV-2 infection were included in the study, with a mean age of 36.9 ± 11.9 years. Most of the participants (85.9%) were < 50 years of age. The male to female ratio was 1.5:1. More than half of the participants were workers (56.5%), while 29.2% were unemployed, 6.7% were retired, and 2.4% were students. Regarding smoking status, 20.1% currently smoked, and 7.9% formally smoked, and 71.9% had never smoked (Table 1). Comorbid conditions were prevalent in 247 (24.7%) participants (Fig. 1). In terms of associated comorbidities, 24.7% of the participants had comorbidities; of these, 16.3% had one comorbidity and 8.2% had two or more comorbidities. The most prevalent comorbidity was diabetes (9.7%), followed by hypertension (7.9%), asthma (5.7%), hyperparathyroidism (2.3%), and allergic disorders (1.8%). Fig. 1 summarizes the recorded comorbidities.

Acute COVID-19 symptoms

Of the participants included in the study, 948 (94.8%) experienced acute COVID-19 symptoms. Of these, 74.7% had fewer than six symptoms. The most common symptoms were fever (68.5%), loss of smell (58%), loss of taste (51.7%), headache (44.7%), and fatigue (40.1%). Table 2 shows the distribution of symptoms of acute SARS-CoV-2 infection.

Table 2
The distribution of symptoms of acute SARS-CoV-2 infection.

| Symptom                  | %     |
|--------------------------|-------|
| Fever                    | 68.5  |
| Loss of smell            | 58.0  |
| Loss of taste            | 51.7  |
| Headache                 | 44.7  |
| Fatigue                  | 40.1  |

Fig. 1. Distribution of comorbid conditions among the entire study cohort (N = 1000) Any comorbidity= 247 (24.7%), 1 morbidity= 163 (16.3%), 2 or more comorbidities= 82 (8.2%).

528
The distribution of acute SARS-CoV-2 infection symptoms (N = 1000). The most commonly used symptom in our population was loss of smell (52.4%), followed by loss of taste (31.1%), fatigue (11.5%), shortness of breath (10.2%), cough (8.9%), and joint pain (8.4%). Of 92 participants with the post-COVID-19 condition, the following symptoms were reported: loss of smell (38%), loss of taste (16.3%), fatigue (7.6%), shortness of breath (5.4%), fever (5.4%), joint pain (4.3%), and headache (3.3%) (Table 3). The most commonly used treatments for relieving symptoms were analgesics or antipyretics (7.5%), vitamins (6.2%), herbal preparations (2.6%), zinc (2.3%), cough syrup/expectorants (2.3%), and strong odors (1.6%). The most aggravating factors were changes in physical activity (2.6%), smoking (1.0%), and cough (0.6%). Similar symptoms were observed in family members in 19.1% of cases. In 31% of participants, the symptoms influenced social and work-related activities. Hospital admission for COVID-19 was reported in 0.9% of participants. Only four deaths (0.4%) occurred subsequent to the acute SARS-CoV-2 infection (Table 4).

Predictors of the post-COVID-19 condition

Univariate logistic regression analysis showed that many factors were associated with an increased risk of the post-COVID-19 condition, including history of acute COVID-19 infection (OR=6.8, 95% CI 2.5–18.8; p < 0.0001), and hospital admission (OR=2.33, 95% CI 1.4–4.0; p = 0.001). Multivariate logistic regression analysis demonstrated that the presence of acute symptoms of COVID-19 and hospital admission were significant independent predictors of post-COVID-19 condition (aOR= 15.0, 95% CI 2.1–109.4; p = 0.008 and aOR= 2.3, 95% CI 1.3–3.9), respectively (Table 5).

Discussion

Persistent post-COVID-19 symptoms have a negative impact on health-related quality of life and exert increased burden on health systems [18,19]. The extent of those symptoms, their predictors, and possible alleviating and aggravating factors were not studied and reported previously for the population of Saudi Arabia. This study identified that late symptoms (beyond 4 weeks of diagnosis) occurred in 22.5% of participants. Similar results were reported in a population-representative study done in the UK, where 21% of the included cases had late symptoms lasting beyond 5 weeks of infection [20]. In contrast, Sudre et al. reported a lower percentage of 13% with symptoms lasting 28 days after symptom onset in another cohort in the UK [21]. In the Netherlands and Belgium, Goertzel et al. reported that over 99% of infected cases did not fully recover within 12 weeks after symptom onset. The huge number of persistent late symptoms could be explained by the fact that the sample was from a Facebook group of patients with persistent complaints [22]. Nehme et al., reported 33% of cases with symptoms 30–45 days after diagnosis in hospital outpatient settings in Switzerland [23]. A large-scale observational study involving 38 participants in Michigan, USA also showed similar results where 32.6% of their participants experienced chronic symptoms [24]. The most common late symptoms in our population were loss of smell, loss of taste, fatigue, shortness of breath, and cough. Fatigue and shortness of breath were also commonly reported in different studies [14,22–24].

Only 5.5% of participants continued to have symptoms more than 12 weeks after diagnosis in this study, compared with 10% and 2% in different studies in the UK [20,21]. The following symptoms were reported: loss of smell, loss of taste, fatigue, shortness of breath, and fever (32.6%, 15.8%, 7.4%, 5.3% and 5.3% of post-COVID-19 symptomatic patients respectively). Loss of smell continued to be the top persistent complaint in our population. This should direct the focus of public education toward the course of olfactory inflammation and set recovery expectations [15].

Hospital admission, female sex and the presence of early symptoms were found to be top predictors for the occurrence of late symptoms in our population. Similarly, a Chinese post-acute COVID-19 investigation identified sex-based differences, with females more likely to experience fatigue and anxiety/depression at 6 months of follow-up [25].

A concerning percentage of those who had the late symptoms beyond 4 weeks (31%), reported that the symptoms affected their social and work-related activities. The majority of patients who had late symptoms (beyond 4 weeks) reported no alleviating (72.7%) or aggravating factors (94.8%).

Our study had limitations due to the nature of a retrospective, cross-sectional design where only a sample of participants was...
### Table 3
The distribution of ongoing symptomatic COVID-19 and post-COVID-19 syndrome patients.

| COVID-19 symptoms | Ongoing symptomatic COVID-19 n = 225 | Post-COVID-19 syndrome n = 92 |
|-------------------|-------------------------------------|-----------------------------|
|                   | Counts | % Total | % of Symptomatic | Counts | % Total | % of Symptomatic |
| Loss of smell     | 118    | 11.8    | 52.4            | 35     | 3.5     | 38              |
| Loss of taste     | 70     | 7       | 31.1            | 15     | 1.5     | 16.3            |
| Fatigue           | 26     | 2.6     | 11.5            | 7      | 0.7     | 7.6             |
| Shortness of breath | 23   | 2.3     | 10.2            | 5      | 0.5     | 5.4             |
| Cough             | 20     | 2       | 8.9             | 2      | 0.2     | 2.2             |
| Joint pain        | 19     | 1.9     | 8.4             | 4      | 0.4     | 4.3             |
| Headache          | 11     | 1.1     | 4.9             | 3      | 0.3     | 3.3             |
| Chest pain        | 11     | 1.1     | 4.9             | 3      | 0.3     | 3.3             |
| Hair loss         | 9      | 0.9     | 4               | 1      | 0.1     | 1.1             |
| Fever             | 5      | 0.5     | 2.2             | 5      | 0.5     | 5.4             |
| Myalgia           | 5      | 0.5     | 2.2             | 1      | 0.1     | 1.1             |
| Diarrhea          | 5      | 0.5     | 2.2             | 1      | 0.1     | 1.1             |
| Sore throat       | 5      | 0.5     | 2.2             | 2      | 0.2     | 2.2             |
| Low mood          | 4      | 0.4     | 1.8             | 2      | 0.2     | 2.2             |
| Loss of appetite  | 3      | 0.3     | 1.3             | 1      | 0.1     | 1.1             |
| Sputum            | 3      | 0.3     | 1.3             | 1      | 0.1     | 1.1             |
| Nausea            | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Numbness          | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Anxiety           | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Chronic sinusitis | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Nasal congestion  | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Dry eye           | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Tinnitus          | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Change of taste   | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Red-eye           | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Dizziness         | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Insomnia          | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Amnesia           | 2      | 0.2     | 0.9             | 1      | 0.1     | 1.1             |
| Abdominal pain    | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |
| Sneezing          | 1      | 0.1     | 0.4             | 1      | 0.1     | 1.1             |

### Table 4
The characteristics of ongoing symptomatic COVID-19, relieving and aggravating factors, and the clinical outcome (total patients: 225).

| Factor                                      | Counts | % of Symptoms |
|---------------------------------------------|--------|---------------|
| Post-COVID-19 syndrome symptoms (95 symptoms) | 55     | 24.4%         |
| Ongoing symptomatic COVID-19 (354 symptoms) | 92     | 40.9%         |
| Duration of persistent symptoms (days):     |        |               |
| Mean±SD                                      | 28.3±34.7 |
| Median (IQR)                                 | 16 (10-1, 32-1) |
| Range                                        | 4.7–139.8 |
| Relieving factors:                          |        |               |
| Analgesic or antipyretic                     | 23     | 7.5           |
| Vitamins                                     | 19     | 6.2           |
| Herbal preparations                         | 8      | 2.6           |
| Zinc                                         | 7      | 2.3           |
| Cough syrup/expectorant                      | 7      | 2.3           |
| Strong odors                                 | 5      | 1.6           |
| Change in physical activity                 | 4      | 1.2           |
| Antibiotic                                   | 3      | 1.0           |
| Nasal drops                                  | 2      | 0.6           |
| Oxygen                                       | 2      | 0.6           |
| Hypnotic                                     | 1      | 0.3           |
| Antidepressants                              | 1      | 0.3           |
| Muscle relaxant                              | 1      | 0.3           |
| Religious practices                         | 1      | 0.3           |
| No reported relieving factor                 | 224    | 72.7          |
| Aggravating factors:                        |        |               |
| Change in physical activity                 | 8      | 2.6           |
| Smoking                                      | 3      | 1.0           |
| Cough                                        | 2      | 0.6           |
| Strong odors                                 | 2      | 0.6           |
| Common cold                                  | 1      | 0.3           |
| No reported aggravating factor               | 292    | 94.8          |
| Similar symptom in family                   | 43     | 19.1          |
| Symptoms affected social and work-related activities | 70 | 31.1 |
| Hospital admission for COVID-19             | 64     | 6.4%          |
| ICU admission for COVID-19                  | 9      | 0.9%          |
| Death after acute SARS-CoV-2 infection      | 4      | 0.4%          |
| Length of hospital stay, days:              |        |               |
| Mean±SD                                      | 8.0±7.9 |
| Range                                        | 1–30   |
Table 5
Factors associated with the occurrence of COVID-19 symptoms beyond 4 weeks of diagnosis.

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
|                     | Mean Diff/Unadjusted OR (95%CI) | P-value | Adjusted OR | P-value |
| Age-years 0.91 (0.86–2.67) | 0.442 | 0.99 (0.9–1.9) | 0.008 | 1.9 (0.6–4.8) | 0.345 |
| Male sex Reference | 0.17 | 0.92 (0.4–1.8) | 0.688 |
| Occupation | 1.4 (1.03–1.87) | 0.17 |
| Working | 0.79 (0.57–1.1) | 0.55 |
| Healthcare employed 0.81 (0.39–1.6) | 0.48 |
| Retired 0.79 (0.42–1.5) | 0.48 |
| Student 2.1 (0.9–5.0) | 0.8 |
| Smoking | 1.4 (0.76–2.6) | 0.255 |
| Current | New Reference | 1.3 (0.9–4.4) | 0.001 |
| Ever | 1.3 (0.9–2.0) | 0.284 |
| No symptoms | Reference | 1.2 (0.8–1.8) | 0.001 |
| Presence of acute symptoms of COVID-19 | 6.8 (2.5–18.8) | 0.001 |
| No symptoms | Reference | 1.2 (0.8–1.8) | 0.001 |
| <6 | 12.8 (1.7–93.5) | 0.012 |
| >6 | 27.6 (27–203.8) | 0.001 |
| Family history of the same symptoms | 0.69 (0.28–2.0) | 0.412 |
| Hospital admission 2.33 (1.4–4.4) | 0.001 |
| Length of stay 0.77 (0.32–2.1) | 0.730 |

* Statistically significant (P < 0.05).

assessed at a certain time. However, the results of this study are valid due to the careful representative sampling methodology.

Conclusions

Saudi patients with the post-acute COVID-19 condition experience a wide range of symptoms, which is consistent with what has been documented in other countries. Loss of smell, loss of taste, shortness of breath, and fatigue are among the persistent symptoms. These symptoms substantially influence social and work-related activities. The impact of this condition should be one of the focus areas for future COVID-19-related research. Regular follow-up of COVID-19 survivors is highly recommended to minimize the burden of the post-acute COVID-19 condition and improve the quality of life of patients.

Funding

This work was supported by the Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2022R290), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Ethical approval

This study was approved by Princess Nourah bint Abdulrahman University IRB log no. 21–0172 on 11 March 2021. All participants were clearly informed about their enrollment in the study and oral consents were obtained. Privacy and confidentiality of patient data were assured throughout the study and only accessed by study primary investigator without identifiers.

Author contributions

FAA, conceptualization, project administration, methodology, Data collection, Data analysis, Writing, Review & Editing. MA, participation in writing the original and final draft. MA, participation in writing the original and final draft. MA, participation in methodology, Data collection, Data analysis, Writing, Review & Editing. MA, participation in writing the original and final draft. MA, participation in methodology, Data collection, Data analysis, Writing, Review & Editing. AA & AA did the data Collection, analysis, writing original draft, editing, resources & investigation. All authors reviewed and approved the submission and take responsibility for the integrity and accuracy of the results.

Data sharing statement

Data are available upon reasonable request.

Declaration of interests

None declared.

References

[1] Sharma A, Tiwari S, Deb MK, Marta JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents 2020;56:106054. https://doi.org/10.1016/j.ijantimicag.2020.106054
[2] Abdelgawad HA, Sayed A, Munir M, Elbery MH, Sayed IM, Kanal MA, et al. Clinical review of COVID-19; pathogenesis, diagnosis, and management. Curr Pharm Des 2021;27:4232–44. https://doi.org/10.2174/1381612826666202122262509
[3] John Hopkins University and Medicine. COVID-19 Dashboard, 2022. (https://covid19.jhu.edu/map.html) (accessed 13 January 2022).
[4] Brooks SK, Webster RK, Smith LE, Woodland I, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020;395:912–20. https://doi.org/10.1016/S0140-6736(20)30468-0
[5] Khan A, Alaswayan Y, Alahmari A, Alowais J, Algwizani A, Alsereni H, et al. COVID-19 in Saudi Arabia: the national health response. East Mediterr Health J 2021;27:1114–11. https://doi.org/10.26719/emhj.21.048
[6] Otto SP, Day T, Arino J, Colijn C, Dushoff J, Li M, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol 2021;31:8918–29. https://doi.org/10.1016/j.cub.2021.06.045
[7] WHO. Tracking SARS-CoV-2 variants. 2021. (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) [accessed 05 15 2021].
[8] Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions, 2021. [accessed 05 15 2021].

[9] Ebada MA, Wadaa-Allah A, Bahbah E, Negida A. An updated review on COVID-19. Infect Disord Drug Targets 2021;21:e16092189190. https://doi.org/10.2174/1871528520666201216163222

[10] Bhat SA, Singh G, Bhat WF, Borole K, Khan AA. Coronavirus disease-2019 and its current scenario–A review. Cln ehealth 2021;4:67–73. https://doi.org/10.1016/j.j.ceh.2021.09.002

[11] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144. https://doi.org/10.1038/s41598-021-95565-8

[12] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGruder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601–15. https://doi.org/10.1038/s41591-021-01283-z

[13] Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 Infection: illness beyond acute infection and public health implications. JAMA 2020;324:2251–2. https://doi.org/10.1001/jama.2020.22717

[14] Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ 2020;370:m3026. https://doi.org/10.1136/bmj.m3026

[15] Centers for Disease Control and Prevention. C. Post-COVID conditions, cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html; 2021.

[16] Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 Post-acute sequelae among adults: 12 month mortality risk. Front Med (Lausanne) 2021;8:778434. https://doi.org/10.3389/fmed.2021.778434

[17] Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreavy MB, Proot AJ, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020;101232. https://doi.org/10.1016/j.ppedcard.2020.101232

[18] del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020;324:1723–4. https://doi.org/10.1001/jama.2020.197719

[19] Logue JK, Franke NM, McCulloch DJ, McDonald D, Magdeson A, Wolf CR, et al. Sequelae in adults at 6 months after COVID-19 infection. (doi.org/). JAMA Netw Open 2021;4:e210830. https://doi.org/10.1001/jamanetworkopen.2021.0830

[20] Rajan S, Khinjani K, Alwan N, et al. (https://www.ncbi.nlm.nih.gov/books/NBK569598/); 2021. (Policy Brief, No. 39.). In: the wake of the pandemic: Preparing for Long COVID [Internet]. Copenhagen Denmark: European Observatory on Health Systems and Policies.

[21] Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID (6):1116. Nat Med 2021;27:626–31. https://doi.org/10.1038/s41591-021-01292-y

[22] Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? EBJ Open Res 2020;6:000542. https://doi.org/10.1183/23120541.000542-2020

[23] Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med, 2021;174:723–5. (doi.org/10.7326/M20–5926);

[24] Carfi A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603–5. https://doi.org/10.1001/jama.2020.12603

[25] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32. https://doi.org/10.1016/S0140-6736(20)32056-8